Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.80 Average Target Price from Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $5.17.

SGMO has been the topic of several recent research reports. Jefferies Financial Group dropped their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, January 27th. Finally, Wells Fargo & Company reduced their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC raised its position in Sangamo Therapeutics by 12.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 13,518 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in Sangamo Therapeutics during the 4th quarter worth $55,000. Two Sigma Advisers LP bought a new position in Sangamo Therapeutics during the 4th quarter worth $722,000. Two Sigma Investments LP grew its holdings in Sangamo Therapeutics by 222.1% during the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after acquiring an additional 698,296 shares during the period. Finally, Rafferty Asset Management LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth about $358,000. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Stock Down 3.5 %

NASDAQ:SGMO opened at $0.84 on Friday. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The firm has a market capitalization of $175.08 million, a P/E ratio of -1.12 and a beta of 1.49. The stock’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, equities research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.